Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 34 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MedTech-related technology assessments and clinical guidelines from NICE in January 2023

In January 2023, four new Interventional Procedures Guidance were published by NICE. Interventional Procedures Guidance (IPG) is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

For the following procedures, NICE concluded that evidence on the safety and efficacy is adequate to support using them with standard arrangements for clinical governance, consent, and audit:

For the following procedures, NICE concluded that evidence on the safety and efficacy is inadequate in quality and quantity, and they should only be used in the context of research:

In January 2023, two new Diagnostic Guidance were published by NICE. The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

NICE assessed devices for remote monitoring of Parkinson’s disease, and conditionally recommended Kinesia 360, KinesiaU, PDMonitor, Personal KinetiGraph (PKG) and STAT‑ON as options to inform treatment only if further evidence is generated and cost impact is managed.

NICE concluded that there is not enough evidence to recommend MRI-based technologies for assessing non-alcoholic fatty liver disease (LiverMultiScan and magnetic resonance elastography, MRE) in people with indeterminate or discordant results from previous fibrosis testing or when transient elastography or acoustic radiation force impulse (ARFI) elastography is unsuitable or has not worked.

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. The three new MIBs published in January 2023 are:

One MedTech-related clinical guideline on hip fracture management was updated in January 2023:

See the full details for guidance here and for MIBs here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.